Breast Cancer Clinical Trial

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Summary

The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects 18 years or older with Prostate Cancer or Breast Cancer with Metastatic Bone Disease Have evidence of recurrence or disease progression
At least one radiographically confirmed metastatic bone lesion
No change of cancer therapy for at least 8 weeks before randomization

Exclusion Criteria:

Have had any prior exposure to bisphosphonate
Have had hip fractures or bilateral hip prothesis fracture of any kind or surgery to bone within the past 12 months
Inadequate renal function or low haemoglobin
Inadequate liver function as demonstrated by serum bilirubin ≥2 times the upper limits of reference range (ULRR) or by alanine aminotransferase (ALT), aspartate aminotransferase(AST) or ALP ≥2.5 times the ULRR (≥5 times the ULRR in the presence of liver metastases). If bone metastases are present and liver function is otherwise considered adequate by the investigator then elevated ALP will not exclude the patient.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

139

Study ID:

NCT00558272

Recruitment Status:

Completed

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Research Site
Pleasant Hill California, , United States
Research Site
Sacramento California, , United States
Research Site
Middlebury Connecticut, , United States
Research Site
Aventura Florida, , United States
Research Site
Baltimore Maryland, , United States
Research Site
Ann Arbor Michigan, , United States
Research Site
Poughkeepsie New York, , United States
Research Site
Winston-salem North Carolina, , United States
Research Site
Hershey Pennsylvania, , United States
Research Site
Edmonton Alberta, , Canada
Research Site
Vancouver British Columbia, , Canada
Research Site
Toronto Ontario, , Canada
Research Site
Montreal Quebec, , Canada
Research Site
Quebec , , Canada
Research Site
Arhus N , , Denmark
Research Site
Frederica , , Denmark
Research Site
Herlev , , Denmark
Research Site
Holstebro , , Denmark
Research Site
Kristiansand , , Norway
Research Site
Oslo , , Norway
Research Site
Lisboa , , Portugal
Research Site
Barcelona Cataluna, , Spain
Research Site
Lerida Cataluna, , Spain
Research Site
Valencia Comunidad Valenciana, , Spain
Research Site
Uppsala , , Sweden
Research Site
Cardiff , , United Kingdom
Research Site
Glasgow , , United Kingdom
Research Site
Manchester , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

139

Study ID:

NCT00558272

Recruitment Status:

Completed

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.